TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11705173

Group type: COMPARATOR
Intervention: Compression stockings (Group 1)
Number of subjects: 274

Group type: COMPARATOR
Intervention: 0.3 ml low‐molecular weight heparin (Group 2)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Compression stockings and 0.3 ml LMWH (Group 3)
Number of subjects: 274
Study: 9140691

Group type: EXPERIMENTAL
Intervention: Amlodipine 20 mg iv (two doses of 10 mg each)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (10 ml, two doses)
Number of subjects: 16
Study: 8198250

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms per nasal cavity and day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3491317

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy and Portacaval shunt
Number of subjects: 64
Study: 29468749

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy lifestyle counselling
Number of subjects: 75

Group type: COMPARATOR
Intervention: Regular-fat cheese
Number of subjects: 75
Study: 27228899

Group type: EXPERIMENTAL
Intervention: Tailored online intervention for physicians including audio-recorded clips
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Tailored online intervention for physicians
Number of subjects: 527
Study: 25104521

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 24506965

Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol combined with candesartan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 40
Study: 20843983

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 231
Study: 17588584

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 16652033

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of abacavir/lamivudine (FDC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Separate entities (abacavir twice daily and lamivudine once daily) (SE)
Number of subjects: 186
Study: 12814254

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (vincristine, lomustine, and prednisone or '8-in-1') with involved-field irradiation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Involved-field irradiation with chemotherapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 250
Study: 11009150

Group type: EXPERIMENTAL
Intervention: Single dose anthelminthic (400 mg albendazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily iron‐folate supplements (36 g iron and 5 mg folate)
Number of subjects: 0
Study: 8774567

Group type: EXPERIMENTAL
Intervention: Oral etoposide (50 mg twice daily for 10 days, 4 cycles)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Standard intravenous chemotherapy (etoposide and vincristine or cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study: 1321543

Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31443887

Group type: EXPERIMENTAL
Intervention: Hatha yoga classes for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health education (HE) classes for 3 months
Number of subjects: 40
Study: 27840322

Group type: EXPERIMENTAL
Intervention: Platinum‐chromium EES
Number of subjects: 2980

Group type: COMPARATOR
Intervention: Cobalt‐chromium EES
Number of subjects: 2980
Study: 25465809

Group type: EXPERIMENTAL
Intervention: Atenolol (25-50mg daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Losartan (25mg daily)
Number of subjects: 17
Study: 24388403

Group type: EXPERIMENTAL
Intervention: Complex motor imagery (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex MI by experienced pianists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex MI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiar actions
Number of subjects: 0
Study: 22435991

Group type: EXPERIMENTAL
Intervention: ICG-augmented diode laser treatment (ICG+DL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Flashlamp-pumped pulsed dye laser (FPDL)
Number of subjects: 31
Study: 20159133

Group type: EXPERIMENTAL
Intervention: Able-bodied participants
Number of subjects: 31

Group type: COMPARATOR
Intervention: Participants with poliomyelitis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Able-bodied participants and participants with poliomyelitis
Number of subjects: 31
Study: 17217359

Group type: EXPERIMENTAL
Intervention: One dose of 400 microgram oral misoprostol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Two doses of 400 microgram oral misoprostol
Number of subjects: 300
Study: 15794383

Group type: EXPERIMENTAL
Intervention: [11C]PK11195 uptake in NAWM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: [11C]PK11195 uptake in T2-lesions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Brain atrophy in MS patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of brain atrophy
Number of subjects: 30
Study: 12499889

Group type: EXPERIMENTAL
Intervention: CsA withdrawal
Number of subjects: 187

Group type: COMPARATOR
Intervention: CsA continuation
Number of subjects: 187
Study: 9462602

Group type: EXPERIMENTAL
Intervention: Closed-loop arbutamine stress echocardiography
Number of subjects: 1070
Study: 8575118

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg and 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg and 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg and 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 5 mg and 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perindopril 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Felodipine ER 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study: 2213283

Group type: EXPERIMENTAL
Intervention: Diuretic-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors or calcium channel blockers
Number of subjects: 0
Study: 420999

Group type: EXPERIMENTAL
Intervention: Grey-scale ultrasonography
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard clinical assessment
Number of subjects: 212
Study: 31584783

Group type: EXPERIMENTAL
Intervention: Kamedis Eczema Therapy Cream (test product)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vehicle (identical test product without botanical combination)
Number of subjects: 39
Study: 28566590

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day for men, 15 mg/day for women)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Metformin (750 mg/day)
Number of subjects: 58
Study: 26272500

Group type: EXPERIMENTAL
Intervention: Continuous training at ventilatory threshold (CTVT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Interval training (IT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continuous training at high intensity (CTHI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All training types (CTHI, CTVT, IT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: End-exercise vigour
Number of subjects: 35
Study: 24105252

Group type: EXPERIMENTAL
Intervention: Bepotastine besilate 10 mg (reference)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bepotastine salicylate 9.64 mg (test)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of both formulations
Number of subjects: 26
Study: 21660896

Group type: EXPERIMENTAL
Intervention: Recall training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Paired-associate learning
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Recognition training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 19487926

Group type: EXPERIMENTAL
Intervention: N-acetylcarnosine eyedrops
Number of subjects: 50500
Study: 16730270

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8010
Study: 15248845

Group type: EXPERIMENTAL
Intervention: Special care group (educational advice on allergen exposure reduction)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Special care group
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 443
Study: 11520524

Group type: EXPERIMENTAL
Intervention: Conventional drugs (diuretics or b-blockers)
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 6614

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 6614
Study: 9291168

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.15-0.2 g/kg body weight, administered monthly for 2 years
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 148
Study: 8326293

Group type: EXPERIMENTAL
Intervention: Simvastatin (0, 10, 20 and 40 mg day‐1 for 6 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pravastatin (0, 10, 20 and 40 mg day‐1 for 6 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both drugs (Simvastatin and Pravastatin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 48
Study: 3732227

Group type: EXPERIMENTAL
Intervention: CO measurement demonstration at the beginning of treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO measurement demonstration at the end of treatment (prior to self-reports)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO measurement demonstration at the end of treatment (subsequent to self-reports)
Number of subjects: 0
Study: 31030644

Group type: EXPERIMENTAL
Intervention: non-linear pedagogy
Number of subjects: 22

Group type: COMPARATOR
Intervention: linear pedagogy
Number of subjects: 22
Study: 30257956

Group type: EXPERIMENTAL
Intervention: autologous fecal microbiota transplantation (auto‐FMT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: no intervention (control)
Number of subjects: 25
Study: 28223082

Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Supportive Therapy of Cognitively Impaired Older Adults (ST‐CI)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both PATH and ST‐CI
Number of subjects: 74
Study: 26163505

Group type: EXPERIMENTAL
Intervention: Designated time appointment system
Number of subjects: 354

Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 354
Study: 23294967

Group type: COMPARATOR
Intervention: Staff training intervention for nurse aides (NAs) focused on offering choice during morning care for 12 weeks.
Number of subjects: 169
Study: 21397541

Group type: EXPERIMENTAL
Intervention: Preemptive approach with regular galactomannan (GM) assays and caspofungin, amphotericin or voriconazole (CAV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Empirical approach with CAV according to established guidelines
Number of subjects: 52
Study: 18978609

Group type: EXPERIMENTAL
Intervention: PWC V O2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PWC HRT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: VT
Number of subjects: 10
Study: 17039508

Group type: EXPERIMENTAL
Intervention: StarClose
Number of subjects: 596

Group type: COMPARATOR
Intervention: Standard Compression
Number of subjects: 596
Study: 12902951

Group type: EXPERIMENTAL
Intervention: ProDisc II arthroplasty
Number of subjects: 39

Group type: COMPARATOR
Intervention: 360 degrees lumbar spinal fusion
Number of subjects: 39
Study: 10858844

Group type: EXPERIMENTAL
Intervention: S‐(+)‐ketamine (1.5 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ketamine‐racemic mixture (3 mg/kg)
Number of subjects: 80
Study: 9350068

Group type: COMPARATOR
Intervention: 20 g of n‐3 PUFA
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.65 g of n‐3 PUFA
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 4 g of n‐3 PUFA
Number of subjects: 94
Study: 1439627

Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac + 200 µg misoprostol)
Number of subjects: 346

Group type: COMPARATOR
Intervention: 50 mg diclofenac
Number of subjects: 346
Study: 3762946

Group type: EXPERIMENTAL
Intervention: Opioid drugs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Naloxone (parenterally)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Naloxone placebo
Number of subjects: 5
Study: 30682359

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1000 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 183
Study: 28039737

Group type: EXPERIMENTAL
Intervention: Rehabilitation after partial glossectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Partial glossectomy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Reconstruction group
Number of subjects: 62
Study: 25912040

Group type: EXPERIMENTAL
Intervention: Experimental soy-based formula 1 (EF1) containing scFOS (2.5 g/L) and mixed carotenoids
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Experimental soy-based formula 2 (EF2) containing scFOS (2.5 g/L) and mixed carotenoids
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control formula (CF) with no scFOS and no mixed carotenoids
Number of subjects: 188
Study: 23771008

Group type: EXPERIMENTAL
Intervention: Swim goggles (test group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Goggles with central lens cut out (control group)
Number of subjects: 125
Study: 22121934

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 40
Study: 19517421

Group type: EXPERIMENTAL
Intervention: Endometrial thickness after medical abortion (mean 14.5 mm for women who underwent D&C)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Endometrial thickness thresholds (dichotomized at 5-mm increments from 10 to 30 mm)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Area under the ROC curve for endometrial thickness
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Mean endometrial thickness for women who did not undergo D&C (10.9 mm)
Number of subjects: 2208
Study: 17923208

Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate topical cream
Number of subjects: 110

Group type: COMPARATOR
Intervention: Moisturizing cream (placebo)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate topical cream (after second treatment)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Moisturizing cream (placebo) (after second treatment)
Number of subjects: 110
Study: 15756159

Group type: EXPERIMENTAL
Intervention: 40 s rest interval group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 160 s rest interval group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 11712401

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lispro insulin
Number of subjects: 0
Study: 9613385

Group type: EXPERIMENTAL
Intervention: Scleral graft
Number of subjects: 25

Group type: COMPARATOR
Intervention: Partial tenotomy with adjuvant antimetabolite (5-fluorouracil or mitomycin C)
Number of subjects: 25
Study: 8084972

Group type: COMPARATOR
Intervention: Unmedicated systolic and diastolic blood pressure levels
Number of subjects: 315

Group type: COMPARATOR
Intervention: Duration of hypertension
Number of subjects: 315
Study: 3050533

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 0
Study: 4371672

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol, dose adjusted to symptoms, for 13 to 20 months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 26
Study: 30295409

Group type: EXPERIMENTAL
Intervention: Withdrawal from long-term use of zopiclone, zolpidem, or temazepam (BZDA) with psychosocial support
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Withdrawal from long-term use of zopiclone, zolpidem, or temazepam (BZDA)
Number of subjects: 92
Study: 28671857

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX) with leucovorin rescue
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Escalating dose MTX with PEG asparaginase without leucovorin rescue
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Age < 10 years at diagnosis
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: US public health insurance
Number of subjects: 192
Study: 25981348

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 5mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 10mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 20mg/day
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 23876953

Group type: EXPERIMENTAL
Intervention: Bass technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scrubbing technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Modified Stillman technique
Number of subjects: 30
Study: 21857142

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5-5 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fluvastatin (20-40 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Switching from fluvastatin to rosuvastatin
Number of subjects: 75
Study: 19216014

Group type: EXPERIMENTAL
Intervention: Focused atorvastatin therapy
Number of subjects: 2442

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2442
Study: 17926823

Group type: EXPERIMENTAL
Intervention: Rituximab + Methotrexate
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Rituximab + Steroid
Number of subjects: 1150
Study: 14716774

Group type: EXPERIMENTAL
Intervention: IFN-alpha-continuous group (3 MU of IFN-alpha three times weekly for 24 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IFN-alpha-intermittent group (3 MU of IFN-alpha daily for 10 days every month for 6 months, then 3 MU daily for 10 days every 3 months for 18 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no IFN-alpha therapy)
Number of subjects: 30
Study: 11246548

Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sunflower oil diet
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wash-in diet rich in saturated fatty acids
Number of subjects: 58
Study: 9218075

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 750 mg b.d.
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. plus amoxycillin 750 mg b.d.
Number of subjects: 381
Study: 8128835

Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA), a cholinesterase inhibitor, chronic dose
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nicotine, acute dose
Number of subjects: 89
Study: 3278638

Group type: EXPERIMENTAL
Intervention: Cholecystoenterostomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Choledochoenterostomy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cholecystoenterostomy (in malignant biliary obstruction subgroup)
Number of subjects: 31
Study: 30926400

Group type: EXPERIMENTAL
Intervention: ReHand tablet application (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Home exercise program on paper (control group)
Number of subjects: 50
Study: 28450428

Group type: EXPERIMENTAL
Intervention: 5As Team intervention
Number of subjects: 28
Study: 26254948

Group type: EXPERIMENTAL
Intervention: Telephone-delivered self-management intervention (T-SM) (n=75)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Telephone-delivered MS education intervention (T-ED) (n=88)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 163
Study: 22981362

Group type: EXPERIMENTAL
Intervention: Transverse coloplasty (TCP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Colonic J-pouch (CJP)
Number of subjects: 106
Study: 21358011

Group type: EXPERIMENTAL
Intervention: Synbiotic (probiotic plus prebiotic)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 41
Study: 18300265

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse 3 times a day for 3 weeks (Arm A)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Double-blind placebo (normal saline) with the same dose and frequency (Arm B)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cryotherapy with crushed ice for 45 minutes during chemotherapy (Arm C)
Number of subjects: 225
Study: 17213254

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: RS
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group of RCT
Number of subjects: 254
Study: 15633323

Group type: EXPERIMENTAL
Intervention: Anesthetic gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Injection anesthesia (lidocaine 2% adrenaline)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Anesthetic gel
Number of subjects: 170

Group type: COMPARATOR
Intervention: Injection anesthesia
Number of subjects: 170
Study: 11734708

Group type: EXPERIMENTAL
Intervention: Oral cefixime for 3 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical polymyxin‐bacitracin for 7 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral cefixime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical polymyxin‐bacitracin
Number of subjects: 80